Cost cutting is Novartis' key to sustaining high R&D spending

04/3/2011 | Wall Street Journal, The

Unlike competitors, Novartis uses cost reduction to keep its funding level for research and development "at the top of the industry," said CEO Joe Jimenez. He is optimistic about the company's ability to generate strong sales growth despite competition from generics. "We have a strategy that can lead us to grow over the next five years despite patent losses and drug price cuts," he said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC